Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
KamadaXTAE:KMDA -0.82%84 EBITDA Margin % is 20.84% as of Mar. 2026, which is 26% above its 10-year median of 16.51. GuruFocus rates XTAE:KMDA with a GF Score™ of 84/100 and a GF Value™ of ₪25.14 (Modestly Undervalued). Among 961 Drug Manufacturers companies, Kamada ranks better than 70.34% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Kamada's EBITDA for the
three
months ended in Mar. 2026 was ₪28.3 Mil. Kamada's Revenue for the
three
months ended in Mar. 2026 was ₪135.9 Mil. Therefore, Kamada's EBITDA margin for the quarter that ended in Mar. 2026 was 20.84%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Kamada EBITDA Margin % Related Terms
Kamada EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Kamada's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTAE:KMDA vs ZTS, UTHR, VTRS: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Kamada's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kamada EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kamada's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Kamada's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kamada (XTAE:KMDA) has a EBITDA Margin % of 20.84% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Kamada and its competitors. This is 26% above median its historical median of 16.51. According to the industry distribution chart, Kamada ranks #285 out of 961 companies in the Drug Manufacturers industry, placing it in the top 29.7%.
Is Kamada's EBITDA Margin % too high?
Kamada's current EBITDA Margin % of 20.84% is 26% above median its 10-year median of 16.51. The Drug Manufacturers industry median EBITDA Margin % is 12.39. Kamada's value of 20.84% is 68.2% above this industry median. Based on the distribution chart, Kamada ranks #285 out of 961 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Kamada has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kamada's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Kamada ranks #285 out of 961 companies for EBITDA Margin %. This puts Kamada in the upper half of its industry. The industry median EBITDA Margin % is 12.39. Kamada's value of 20.84% is 68.2% above this benchmark. While the company's 10-year median is 16.51 vs. the industry median of 12.39, Kamada has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.39, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kamada's current EBITDA Margin % of 20.84% is 68.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Kamada and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kamada's current EBITDA Margin % is 20.84%, which is 26% above median its own 10-year median of 16.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kamada stock overvalued right now?
Based on GuruFocus' analysis, Kamada (XTAE:KMDA) is currently considered Modestly Undervalued. The stock's GF Value™ is ₪25.14, compared to a current price of ₪21.80 — trading 13.3% below its estimated fair value. The current EBITDA Margin % is 20.84%, which is 26% above median its 10-year median of 16.51 and 68.2% above the Drug Manufacturers industry median of 12.39. Kamada's overall GF Score™ is 84/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Kamada (XTAE:KMDA), the current EBITDA Margin % is 20.84% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kamada (XTAE:KMDA) Overvalued in 2026?
Based on GuruFocus' analysis, Kamada stock appears to be undervalued.
The current stock price of ₪21.80 is trading 13.3% below its estimated GF Value™ of ₪25.14.
GuruFocus considers Kamada to be Modestly Undervalued.
Key valuation signals for XTAE:KMDA:
EBITDA Margin %: 20.84% (26% above median its 10-year median of 16.51)
GF Value™: ₪25.14 vs. price of ₪21.80 (13.3% below fair value)
Industry Position: 68.2% above the Drug Manufacturers median (#285 of 961)
No single metric tells the full story. See the XTAE:KMDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
84GF Score
Get the complete analysis for XTAE:KMDA
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTAE:KMDA has been successfully added to your 
